ClinicalTrials.gg
CompletedNCT01587885Updated Mar 11, 2015Results posted

Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)

A Phase 4 interventional study of Omeprazole 20 mg + Sodium Bicarbonate 1100 mg and Omeprazole 20 mg in Heartburn, sponsored by Bayer. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-11.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate a single ingredient product (omeprazole 20 mg) with a combination product capsule (omeprazole 20 mg + sodium bicarbonate 1100 mg) in participants with frequent heartburn.

02

Conditions studied

  • Heartburn

Browse trials for

Keywords

  • Frequent Heartburn
  • Omeprazole
  • Omeprazole, sodium bicarbonate drug combination
  • Gastrointestinal Agents
  • Therapeutic Uses
  • Pharmacologic Actions
  • Enzyme Inhibitors
  • Molecular Mechanisms of Pharmacological Action
  • Proton Pump Inhibitors
03

In context

Heartburn

154 studies on the registry are indexed under Heartburn; 12 are open to participants now.

This study's enrollment of 48 is below the median of 100 across 127 interventional studies indexed under Heartburn.

Browse Heartburn studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of must demonstrate a negative urine pregnancy test and agree to use an acceptable method of
  • Suffer from frequent heartburn
  • Refrain from taking non-study medicine or treatment for heartburn for the duration of the study
  • Be free of any disease that requires a physician's care
  • Read and understand English

Exclusion criteria

Exclusion Criteria:

  • Any significant medical condition which is a to the use of omeprazole or sodium bicarbonate
  • Known to the study drugs or any components
  • Experiencing any of the following: trouble or pain with swallowing food, vomiting with blood, bloody or black stools
  • Participation in another study within 4 weeks prior to the screening visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Omeprazole 20 mg + Sodium Bicarbonate 1100 mg

    Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.

    Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg · Drug: Omeprazole 20 mg

  • Active comparator
    Omeprazole 20 mg

    Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.

    Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg · Drug: Omeprazole 20 mg

Interventions

  • DrugOmeprazole 20 mg + Sodium Bicarbonate 1100 mg

    Drug page: Omeprazole

    Capsules, orally

    Also known as: Zegerid™

  • Tablets, orally

    Also known as: Prilosec OTC™

06

What researchers measure

Primary outcomes

  1. Time-to-onset of Heartburn Relief

    Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.

    Time frame: Start of treatment until onset of heartburn relief, up to 24 hours

Secondary outcomes

  1. Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time

    Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.

    Time frame: Start of treatment until onset of heartburn relief, up to 72 hours

  2. Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire

    Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.

    Time frame: At end of study (approx. Study Day 40)

  3. Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire

    Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.

    Time frame: At end of study (approx. Study Day 40)

  4. Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire

    Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.

    Time frame: At end of study (approx. Study Day 40)

  5. Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire

    End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.

    Time frame: End of treatment period 1 and end of treatment period 2

07

Results

Posted May 22, 2013

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneOmeprazole 20mg+Sodium Bicarbonate 1100mg Then Omeprazole 20mgOmeprazole 20mg Then Omeprazole 20mg+Sodium Bicarbonate 1100mg
Started2622
Completed2619
Not completed03
Withdrew: Failure to return01
Withdrew: Protocol violation02
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneOmeprazole 20mg+Sodium Bicarbonate 1100mg Then Omeprazole 20mgOmeprazole 20mg Then Omeprazole 20mg+Sodium Bicarbonate 1100mg
Started2619
Completed2619
Not completed00

Outcome measures

PrimaryTime-to-onset of Heartburn Relief

Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.

Time frame:
Start of treatment until onset of heartburn relief, up to 24 hours
Reported as:
Median · Minutes
Time-to-onset of Heartburn Relief
MinutesOmeprazole 20 mg + Sodium Bicarbonate 1100 mgOmeprazole 20 mg
Time-to-onset of Heartburn Relief30.0 (30.0 to 75.0)60.0 (30.0 to 105.0)
Statistical analysis
  • Omeprazole 20 mg + Sodium Bicarbonate 1100 mg vs Omeprazole 20 mg · Regression, Cox · p = <0.0480 · Hazard ratio (hr): 1.548
SecondaryPercentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time

Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows: Absent (0): Heartburn is not present. Mild (1): Heartburn did not last long or was easily tolerated. Moderate (2): Heartburn caused discomfort and interrupted usual activities. Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.

Time frame:
Start of treatment until onset of heartburn relief, up to 72 hours
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time
percentage of participantsOmeprazole 20 mg + Sodium Bicarbonate 1100 mgOmeprazole 20 mg
≤15 minutes20.513.6
≤30 minutes52.327.3
≤60 minutes75.061.4
≤90 minutes90.975.0
≤120 minutes95.588.6
≤180 minutes100.090.9
≤1440 minutes (24 hours)100.093.2
≤2880 minutes (48 hours)100.095.5
≤4320 minutes (72 hours)100.0100.0
SecondaryNumber of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire

Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.

Time frame:
At end of study (approx. Study Day 40)
Reported as:
Number · participants
Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire
participantsAll Treated Participants
Preferred omeprazole+sodium bicarbonate14
Preferred omeprazole17
Preferred both equally9
Missing data8
SecondaryNumber of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire

Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.

Time frame:
At end of study (approx. Study Day 40)
Reported as:
Number · participants
Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire
participantsAll Treated Participants
Preferred omeprazole+sodium bicarbonate16
Preferred omeprazole16
Preferred both equally7
Preferred neither1
Missing data8
SecondaryNumber of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire

Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.

Time frame:
At end of study (approx. Study Day 40)
Reported as:
Number · participants
Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire
participantsAll Treated Participants
Preferred omeprazole+sodium bicarbonate17
Preferred omeprazole17
Preferred both equally6
Missing data8
SecondaryPercentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire

End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.

Time frame:
End of treatment period 1 and end of treatment period 2
Reported as:
Number · percentage of partcipants
Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire
percentage of partcipantsOmeprazole 20 mg + Sodium Bicarbonate 1100 mgOmeprazole 20 mg
heartburn symptoms affected daily activities30.030.0
heartburn symtoms caused trouble falling asleep27.525.0
heartburn symptoms awoke participant22.532.5
slept on incline due to heartburn symptoms35.047.5
medicine helped with full night's rest90.095.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Omeprazole 20 mg + Sodium Bicarbonate 1100 mg—0/45 (0%)0/45 (0%)
Omeprazole 20 mg—0/48 (0%)0/48 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean48.3 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female31
Male17
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2012
First posted
Apr 30, 2012
Start
Jan 2012
Primary completionActual
Apr 2012
CompletionActual
May 2012
Results first posted
May 22, 2013
Last update
Mar 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01587885
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 30, 2012
Start date
Jan 2012
Primary completion
Apr 2012
Completion
May 2012
Results posted
May 22, 2013
Last update
Mar 11, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omeprazole

Start the discussion